Discover
ARQT
Arcutis Biotherapeutics, Inc.
25.29
2 x 25.29
1 x 25.78
bid
ask
-
1.14
4.31%
undefined @ 04:00 PM
25.31 +0.02 (0.08%)
| Ytd | -12.91% | |
| 1y | 79.11% |
25.27
day range
26.88
14.12
52 week range
31.20
| Open | 26.68 | Prev Close | 26.43 | Low | 25.27 | High | 26.88 | Mkt Cap | 3.16B |
| Vol | 2.42M | Avg Vol | 1.75M | EPS | 0.21 | P/E | 120.43 | Forward P/E | 20.05 |
| Beta | 1.53 | Short Ratio | 7.34 | Inst. Own | 108.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 25.45 | 200-d Avg | 25.33 | 1yr Est | 36.63 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-10-27 | 2026-09 | 0.05 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | 0.06 | 0.11 | 0.05 | 99.71% |
| 2026-05-06 | 2026-03 | -0.02 | -0.09 | -0.07 | -350.00% |
| 2026-02-25 | 2025-12 | 0.03 | 0.13 | 0.1 | 333.33% |
| 2025-10-28 | 2025-09 | -0.1 | 0.06 | 0.16 | 160.00% |
| 2025-08-06 | 2025-06 | -0.18 | -0.13 | 0.05 | 27.78% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-06 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-08-06 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-06 | Needham | Upgrade | Buy | Buy |
| 2026-05-07 | Needham | Upgrade | Buy | Buy |
| 2026-03-02 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-02-27 | Guggenheim | Upgrade | Buy | Buy |
Profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-02 | BURNETT PATRICK | Officer | 119.29K | Sale |
| 2025-06-11 | CHAUDHURI BHASKAR | Director | 917.81K | Stock Award(Grant) |
| 2026-03-01 | EDWARDS LARRY TODD | Officer | 175.18K | Sale |
| 2026-06-04 | HERON PATRICK J | Director | 8.87M | Stock Award(Grant) |
| 2026-08-02 | MATSUDA MASARU | Officer | 126.17K | Sale |
| 2026-07-14 | PEETZ CHRISTOPHER | Director | 191.82K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Suvretta Capital Management, LLC | 12.33M | 311.75M | 9.86% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 9.87M | 249.73M | 7.89% |
| 2026-03-30 | Blackrock Inc. | 9.20M | 232.68M | 7.36% |
| 2026-03-30 | Rubric Capital Management LP | 8.27M | 209.19M | 6.61% |
| 2026-03-30 | State Street Corporation | 6.30M | 159.23M | 5.03% |
| 2026-03-30 | Polar Capital Holdings PLC | 5.67M | 143.32M | 4.53% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.51M | 88.84M | 2.81% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 2.95M | 74.73M | 2.36% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.90M | 73.43M | 2.32% |
| 2026-03-30 | Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. | 1.74M | 44.05M | 1.39% |
| 2026-06-29 | American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.47M | 37.09M | 1.17% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.24M | 31.42M | 0.99% |